A5079052740- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Brain Metastases and Treatment
- Neurofibromatosis and Schwannoma Cases
- Radiomics and Machine Learning in Medical Imaging
- Vascular Malformations Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Head and Neck Surgical Oncology
- Lung Cancer Research Studies
- Medical Imaging Techniques and Applications
- Management of metastatic bone disease
- RNA Interference and Gene Delivery
- Ophthalmology and Eye Disorders
- Cerebrospinal fluid and hydrocephalus
- Advanced Radiotherapy Techniques
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Sarcoma Diagnosis and Treatment
- Nanoplatforms for cancer theranostics
- Brain Tumor Detection and Classification
- Teratomas and Epidermoid Cysts
- Nanoparticle-Based Drug Delivery
Seoul National University Bundang Hospital
2016-2025
Seoul National University
2016-2025
Seoul National University Children's Hospital
2010-2023
Daegu Catholic University Medical Center
2023
National University College
2008-2022
New Generation University College
1997-2022
Seoul National University Hospital
1999-2021
Armed Forces Capital Hospital
2021
Weatherford College
2020-2021
Gyeongsang National University Hospital
2021
Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric to the tumor.To investigate whether TTFields improves progression-free overall survival of patients glioblastoma, a fatal disease commonly recurs at initial tumor site or in central nervous system.In this randomized, open-label trial, 695 whose was resected biopsied had completed concomitant...
Purpose To evaluate the effect of middle meningeal artery (MMA) embolization on chronic subdural hematoma (CSDH) and compare treatment outcomes MMA conventional treatment. Materials Methods All consecutive patients 20 years or older with CSDH were assessed for eligibility. CSDHs a focal location, thickness 10 mm less, no mass effect, underlying conditions excluded. Seventy-two prospectively enrolled underwent (embolization group; as sole in 27 [37.5%] asymptomatic additional removal symptom...
<h3>Importance</h3> Tumor-treating fields (TTFields) therapy improves both progression-free and overall survival in patients with glioblastoma. There is a need to assess the influence of TTFields on patients’ health-related quality life (HRQoL). <h3>Objective</h3> To examine association HRQoL among <h3>Design, Setting, Participants</h3> This secondary analysis EF-14, phase 3 randomized clinical trial, compares temozolomide or alone 695 glioblastoma after completion radiochemotherapy....
To evaluate the hearing preservation rate and to determine its prognostic factors after gamma knife (GK) stereotactic radiosurgery (SRS) in patients with vestibular schwannoma, authors used a prospective study design analyze these patients.Between December 1997 January 2002, 25 schwannoma serviceable were enrolled current study. The median tumor volume was 3.0 cc (0.16-9.1 cc). prescription dose 12.0 +/- 0.7 gray at an isodose line of 49.8 1.1%. control complications evaluated by focusing on...
Abstract Background Tumor treating fields (TTFields) is a non-invasive, antimitotic therapy. In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) improved progression free (PFS) and overall survival (OS) versus TMZ alone. Previous data indicate ≥ 75% daily compliance improves outcomes. We analyzed from TTFields/TMZ patients study to correlate with PFS OS identify potential lower boundary for clinical Methods Compliance was assessed by usage...
This study evaluated the toxicity profiles of temozolomide in treatment malignant glioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed medical records 300 patients treated with two institutions Korea between 2004 and 2010. Two hundred nine experienced a total 618 toxicities during therapy. A 84.8% were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 2, while 15.2% 3 4. Among hematologic toxicities, thrombocytopenia (13.7%), anemia (11.0%), AST/ALT...
BACKGROUND A chemosensitizing effect of levetiracetam (LEV) has been suggested because LEV inhibits O‐6 methylguanine‐DNA methyltransferase (MGMT). However, the survival benefit not clinically documented. The objective this study was to assess compared with other antiepileptic drugs as a chemosensitizer temozolomide for patients glioblastoma. METHODS In total, 103 consecutive primary glioblastoma who received concomitant chemoradiotherapy and adjuvant chemotherapy were retrospectively...
To determine the benefit of surgical management in recurrent glioblastoma, we analyzed a series patients with glioblastoma who had undergone surgery, and devised new scale to predict their survival. Clinical data from 55 consecutive were evaluated after management. Kaplan–Meier survival analysis Cox proportional hazards regression modeling used identify prognostic variables for development predictive scale. After multivariate analysis, performance status (P = .078) ependymal involvement...
Pseudoprogression is a major diagnostic dilemma in current treatment protocols for malignant gliomas that involve concurrent chemoradiotherapy. We hypothesized methylation-specific multiplex ligation probe amplification (MS-MLPA), an assay permits semiquantitative evaluation of promoter methylation, may be used to diagnose pseudoprogression based on the quantification methylation status O(6)-methylguanine DNA methyltransferase (MGMT) promoter. examined ratio MGMT with MS-MLPA 48 samples from...
<h3>Objective</h3> The radiological characteristics of World Health Organization grade III oligodendroglial tumours in relation to chromosome 1p and 19q deletions were analysed. <h3>Methods</h3> 56 patients recently diagnosed with anaplastic oligodendroglioma (AO, n=49) or oligoastrocytoma (AOA, n=7) studied. Their preoperative magnetic resonance images examined. Deletions determined using the fluorescence situ hybridisation method. Both chromosomes had (1p19q codeletion) 39 (36 AO 3 AOA)....
Supplementary motor area (SMA) resection often induces postoperative contralateral hemiparesis or speech disturbance. This study was performed to assess the neurological impairments that follow SMA and risk factors associated with these deficits.The records for patients who had undergone pharmacologically intractable epilepsy between 1994 2010 were gleaned from an surgery database retrospectively reviewed in this study.Forty-three underwent intraoperative cortical stimulation mapping while...